[Development of molecular analysis by digital PCR for clinical practice: positioning, current applications and perspectives].

Développement des analyses moléculaires par PCR digitale pour la pratique clinique : positionnement, applications actuelles et perspectives.

Journal

Annales de biologie clinique
ISSN: 1950-6112
Titre abrégé: Ann Biol Clin (Paris)
Pays: France
ID NLM: 2984690R

Informations de publication

Date de publication:
01 12 2019
Historique:
entrez: 21 12 2019
pubmed: 21 12 2019
medline: 12 5 2020
Statut: ppublish

Résumé

This review is the second part of the workshop on digital PCR (dPCR) proposed by the working group of the French society of clinical biology. The first part of the paper discusses the advantages and limitations of dPCR for the search of different molecular abnormalities such as point mutations, copy number variants, DNA methylation, RNA analysis and a more innovative application, the single-cell dPCR. This synthesis makes it possible to propose a positioning of the dPCR compared to the other available technologies in a medical laboratory. In a second part, the main current applications of the dPCR will be addressed including the oncology of solid tumors and liquid biopsies, oncohematology and the follow-up of hemopathies treatments by hematopoietic stem cell transplantation. We will also detail non-invasive prenatal diagnosis and diagnosis of mosaic genetic disease, using the example of McCune-Albright syndrome. Several French specialists in the field who have implemented these techniques in their laboratory have written these different examples of applications jointly. In summary, this manuscript offers an up-to-date view of the positioning of dPCR in relation to other existing technologies in order to best meet the expectations of precision medicine.

Identifiants

pubmed: 31859639
pii: abc.2019.1502
doi: 10.1684/abc.2019.1502
doi:

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

619-637

Auteurs

Jérôme Alexandre Denis (JA)

Sorbonne Université, Faculté de médecine, Institut universitaire en cancérologie ; Service de biochimie endocrinienne et oncologique, DMU Biogen, Hôpitaux universitaires Pitié-Salpêtrière-Charles Foix, Assistance Publique-Hôpitaux de Paris, AP-HP Sorbonne Université ; Inserm UMR S_938, Centre de recherche de Saint-Antoine, Biologie et thérapeutiques du cancer, Paris, France.

Alexandre Perrier (A)

Service de génétique et biologie moléculaires, HUPC Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, AP-HP, Paris, France.

Juliette Nectoux (J)

Service de génétique et biologie moléculaires, HUPC Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, AP-HP, Paris, France.

Pierre-Jean Lamy (PJ)

Institut d'analyse génomique-Imagenome, Labosud, Montpellier, France.

Anne-Sophie Alary (AS)

Service d'hématologie biologique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, AP-HP, Paris, France.

Nasrin Sarafan-Vasseur (N)

Université de Rouen Normandie ; Inserm U1245, IRON group, Centre for genomic and personalized medicine, Rouen, France.

Daniel Henaff (D)

ID Solutions, Grabels, France.

Benoit Busser (B)

Unité de génétique moléculaire - maladies héréditaires et oncologie, CHU Grenoble Alpes, Grenoble, France ; Institute for advanced biosciences, UGA/Inserm U1209/CNRS UMR5309, Grenoble, France.

Romain Appay (R)

Service d'anatomie pathologique et neuropathologie, Assistance Publique Hôpitaux de Marseille, AP-HM, Marseille, France.

Pascal Pedini (P)

Laboratoire d'immunogénétique, EFS Provence-Alpes-Côte-d'Azur-Corse, Marseille, France, Aix Marseille Université, CNRS, EFS, ADES, Marseille, France.

Pauline Romanet (P)

Aix Marseille Université, APHM, Inserm, MMG, Laboratoire de biologie moléculaire, Hôpital de La Conception, Marseille, France.

Valerie Taly (V)

Inserm UMR-S1147, CNRS SNC5014 ; Université Paris-Descartes, Equipe labellisée ligue nationale contre le cancer, Paris, France.

Frederic Fina (F)

ID Solutions, Grabels, France, Service d'anatomie pathologique et neuropathologie, Assistance Publique Hôpitaux de Marseille, AP-HM, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH